Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PLX

Protalix BioTherapeutics Inc.

Nov 29 • 09:32AM ET

1.41

Dollar change +0.05
Percentage change 3.68	%

Healthcare • Biotechnology • Israel • AMEX

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	34.47	EPS (ttm)	0.04	Insider Own	11.30%	Shs Outstand	72.95M	Perf Week	0.00%
Market Cap	102.86M	Forward P/E	9.72	EPS next Y	0.14	Insider Trans	0.79%	Shs Float	64.71M	Perf Month	-5.37%
Income	10.62M	PEG	1.38	EPS next Q	-0.03	Inst Own	13.41%	Short Float / Ratio	9.21% / 13.74	Perf Quarter	-26.56%
Sales	63.62M	P/S	1.62	EPS this Y	133.87%	Inst Trans	-5.61%	Short Interest	5.96M	Perf Half Y	-32.54%
Book/sh	0.52	P/B	2.69	EPS next Y	38.10%	ROA	14.72%	Target Price	13.00	Perf Year	27.03%
Cash/sh	0.56	P/C	2.51	EPS next 5Y	25.00%	ROE	79.42%	52W Range	1.07 - 3.55	Perf YTD	2.92%
Dividend	-	P/FCF	-	EPS past 5Y	45.43%	ROI	24.83%	52W High	-60.28%	Beta	1.13
Dividend %	-	Quick Ratio	1.18	Sales past 5Y	24.47%	Gross Margin	74.03%	52W Low	31.78%	ATR	0.09
Employees	197	Current Ratio	1.67	Sales Q/Q	-27.06%	Oper. Margin	21.34%	RSI (14)	45.97	Volatility	4.24% 7.03%
Optionable	Yes	Debt/Eq	0.68	EPS Q/Q	40.08%	Profit Margin	16.69%	Rel Volume	0.35	Prev Close	1.36
Shortable	Yes	LT Debt/Eq	0.12	Earnings	Nov 06 BMO	Payout	-	Avg Volume	433.77K	Price	1.41
Recom	1.00	SMA20	-3.75%	SMA50	-7.57%	SMA200	-27.12%	Volume	8,381	Change	3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$3 → $11
Apr-17-17	Reiterated	Rodman & Renshaw	Buy	$4 → $5
Apr-04-16	Initiated	Rodman & Renshaw	Buy	$3.50
Apr-23-15	Upgrade	Jefferies	Hold → Buy	$2 → $2.60
Nov-12-14	Reiterated	R. F. Lafferty	Buy	$8 → $5
Jan-24-14	Initiated	R. F. Lafferty	Buy	$8
May-02-12	Reiterated	Oppenheimer	Outperform	$9 → $11
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $8
Apr-30-12	Downgrade	Auriga	Buy → Hold	$8 → $8
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy	$10
Nov-09-10	Reiterated	Oppenheimer	Outperform	$10 → $12
Oct-14-10	Reiterated	UBS	Buy	$9 → $10.75
Dec-02-09	Reiterated	Hapoalim	Outperform	$10 → $12
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform	$10
Dec-01-08	Reiterated	Oppenheimer	Outperform	$6 → $4
Mar-11-08	Initiated	UBS	Buy	$6
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform	$7

Show Previous Ratings

Nov-07-23 09:04AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:04AM	Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results (GuruFocus.com) -18.38%
06:58AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results (PR Newswire)
Oct-30-23 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 (PR Newswire)
06:50AM	Loading…
Oct-09-23 06:50AM	Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel (PR Newswire) -6.71%
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-06-23 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-08-23 09:14AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	PLX: Second Quarter Results (Zacks)
Aug-07-23 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results (PR Newswire) +14.46%
Aug-01-23 06:50AM	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-31-23 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 (PR Newswire)
Jun-08-23 06:50AM	Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease (PR Newswire)
May-30-23 11:00AM	PLX: Back of the Envelope (Zacks Small Cap Research)
06:50AM	Loading…
06:50AM	Protalix BioTherapeutics Issues Letter to Stockholders (PR Newswire)
May-23-23 06:50AM	Protalix BioTherapeutics set to join Russell 3000® Index (PR Newswire) +7.55%
May-18-23 06:50AM	Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases (PR Newswire) -9.32%
May-11-23 07:59AM	PLX: FDA Approval of Elfabrio (Zacks Small Cap Research) -13.27%
May-10-23 04:16PM	Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics (Benzinga)
06:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com) -7.03%
May-05-23 07:26AM	PLX: One Down, One to Go (Zacks Small Cap Research)
06:46AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease (PR Newswire)
May-04-23 06:50AM	Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results (PR Newswire) +6.67%
Apr-27-23 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023 (PR Newswire)
Mar-21-23 06:50AM	Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout (PR Newswire)
Mar-13-23 06:50AM	Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank (PR Newswire)
Feb-28-23 08:52PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
04:32AM	PLX: May is a Big Month (Zacks Small Cap Research)
06:30AM	Loading…
Feb-27-23 06:30AM	Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results (PR Newswire)
Feb-24-23 09:15AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease (PR Newswire) +7.06%
Feb-21-23 06:55AM	Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium 2023 (PR Newswire)
06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023 (PR Newswire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research) +6.99%
Jan-03-23 06:50AM	Protalix BioTherapeutics Issues 2023 Letter to Stockholders (PR Newswire)
Dec-21-22 04:30PM	Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange (PR Newswire)
Dec-05-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease (PR Newswire) +5.31%
Dec-04-22 09:00AM	Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102 (PR Newswire)
Nov-30-22 02:59PM	Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment (News Direct)
Nov-15-22 04:46AM	PLX: BLA Submitted: 1H:23 Responses (Zacks Small Cap Research)
Nov-14-22 06:50AM	Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results (PR Newswire)
06:30AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease (PR Newswire)
Nov-07-22 06:50AM	Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 (PR Newswire)
Sep-21-22 08:00AM	Under The Hood Of Options Chain Implications Understanding How Options Data Can Help Inform Investment Decisions (News Direct)
Sep-12-22 12:40PM	Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Sep-06-22 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-16-22 05:55AM	PLX: Eyes on Upcoming BLA Resubmission (Zacks Small Cap Research)
Aug-15-22 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results (PR Newswire)
Aug-08-22 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 (PR Newswire)
Jun-30-22 04:30PM	Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors (PR Newswire)
Jun-14-22 09:23AM	10 Popular Penny Stocks on Robinhood (Insider Monkey)
May-26-22 04:30PM	Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease (PR Newswire)
May-17-22 06:13AM	PLX: First Quarter Financial and Operational Review (Zacks Small Cap Research)
May-16-22 06:50AM	Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results (PR Newswire)
May-09-22 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022 (PR Newswire) -7.49%
Apr-07-22 10:05AM	10 Penny Stocks to Buy in April (Insider Monkey) -9.62%
Apr-05-22 07:40AM	PLX: Topline Results from BALANCE (Zacks Small Cap Research)
Apr-04-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease (PR Newswire) +41.90%
Apr-01-22 06:22AM	PLX: Fourth Quarter and Fiscal Year 2021 Financial and Operational Review (Zacks Small Cap Research)
Mar-31-22 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results (PR Newswire)
Mar-24-22 06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022 (PR Newswire)
Mar-18-22 09:54AM	Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease (Benzinga) +12.89%
06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease (PR Newswire)
Mar-07-22 07:00AM	Revenue Diversification Strategy Continues to Deliver (PR Newswire)
Feb-28-22 04:45AM	PLX: MAA Submitted (Zacks Small Cap Research)
Feb-24-22 07:27AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease (PR Newswire)
Feb-03-22 06:50AM	Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium 2022 (PR Newswire)
Dec-22-21 06:50AM	Protalix BioTherapeutics Issues 2021 Letter to Stockholders (PR Newswire)
Nov-15-21 10:18AM	PLX: Third Quarter Update (Zacks Small Cap Research)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update (PR Newswire)
Nov-08-21 06:50AM	Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 (PR Newswire)
Oct-15-21 08:37AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease (PR Newswire)
08:00AM	PLX: Type A Meeting Provides Clarity (Zacks Small Cap Research)
Oct-11-21 06:50AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease (PR Newswire) -12.78%
Aug-26-21 06:50AM	Protalix BioTherapeutics Announces Closing of Private Note Exchange (PR Newswire)
Aug-18-21 06:06AM	PLX: Debt Maturities Resolved (Zacks Small Cap Research)
Aug-16-21 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update (PR Newswire)
Aug-13-21 06:50AM	Protalix BioTherapeutics Announces Private Note Exchange (PR Newswire) -9.46%
Aug-09-21 07:15AM	Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 (PR Newswire) +7.33%
Aug-02-21 06:50AM	Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA (PR Newswire)
Jun-30-21 09:56AM	Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy? (Insider Monkey)
Jun-28-21 06:50AM	Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021 (PR Newswire)
Jun-07-21 10:18PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX (GlobeNewswire)
Jun-05-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX (Newsfile)
Jun-03-21 09:28AM	PLX: BALANCE: Interim Results (Zacks Small Cap Research) -10.48%
09:28AM	PLX: BALANCE: Interim Analysis (Zacks Small Cap Research)
12:30AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX (PR Newswire)
Jun-02-21 12:10PM	Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102 (Benzinga) -16.78%
06:50AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease (PR Newswire)
May-25-21 06:50AM	PLX: 1Q:21 Results & Next Steps (Zacks Small Cap Research)
May-14-21 06:50AM	Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update (PR Newswire)
06:45AM	Protalix Biotherapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
May-07-21 10:30AM	Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021 (PR Newswire)
Apr-29-21 05:45AM	PLX: Pandemic Backup Impedes FDA Site Survey (Zacks Small Cap Research) -9.92%
Apr-28-21 03:25PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) Investigation (ACCESSWIRE) -32.59%
01:44PM	Why Protalix BioTherapeutics Stock Is Plunging Today (Motley Fool)
01:27PM	Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA (PR Newswire)
06:21AM	Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease (Benzinga)
01:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA (PR Newswire)

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bashan Dror	PRESIDENT AND CEO	Oct 19	Buy	1.40	64,516	90,484	132,516	Oct 20 06:50 AM
Schwartz Aharon	Director	Jan 03	Buy	1.42	110,000	155,815	174,000	Jan 05 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLX

Protalix BioTherapeutics Inc.

Upgrade your FINVIZ experience